<p>Kenneth Kelley of PaxVax in the U.S. seeks to develop a low-cost, single-dose, oral polio vaccine using a live, safe adenovirus containing protein-encoding genes from poliovirus. If successful, this vaccine can be used to eradicate polio while eliminating the risks of vaccine-derived polio disease and poliovirus re-introduction.</p>


Kenneth Kelley of PaxVax in the U.S. seeks to develop a low-cost, single-dose, oral polio vaccine using a live, safe adenovirus containing protein-encoding genes from poliovirus. If successful, this vaccine can be used to eradicate polio while eliminating the risks of vaccine-derived polio disease and poliovirus re-introduction.